Giant cell tumor of bone is a benign bone tumor that occurs more frequently in our Oriental population, preferably between 20 and 40. Although it is a benign tumor, it has a strong local aggressiveness. Giant cell tumors of bone that occur in the spine are prone to pathological fractures and compression of the spinal cord and nerves, and complete surgical excision has been the mainstay of treatment for spinal cell tumors. However, because the tumor is located in a special anatomical part of the spine, surrounded by important tissue structures such as the spinal cord and large blood vessels, it is often not excised extensively enough to avoid damage to the above structures. Therefore, there is a recurrence rate of about 25% after spinal giant cell tumor surgery. How to reduce recurrence after surgery? Radiation therapy is an effective method, but it has been reported to induce tumor malignancy, so it is not a foolproof solution. Now there is a new drug called denosumab, which is produced by Amgen (AMGEN) and is originally a treatment for osteoporosis. The principle is that it can inhibit osteoclasts, thus reducing bone loss. The drug was borrowed for the treatment of giant cell tumors because the tumor cells in giant cell tumors have great similarity to osteoclasts. Through a series of clinical observations, it was found that denosumab could cause massive necrosis in giant cell tumor of bone, and its effect was superior to that of previously used bisphosphonates and interferon, with fewer side effects than the above two drugs. If the drug is started before surgery, it can sometimes simplify the surgery and reduce the recurrence of tumor after surgery. For patients with recurrence, the drug can shrink the tumor and facilitate reoperation. Denosumab is extremely easy to use, being administered only once a month and by subcutaneous injection. Although tooth loss and jaw necrosis have been reported, the incidence is very low. However, the problem is that although the drug has become a routine drug for giant cell tumor of bone abroad, it has not yet entered the Chinese market, which means that it is not yet available in China. Although there are companies representing the drug to start clinical trials in China, and it is said to be in the stage of recruiting patients (clinical observation of osteoporosis cases as an anti-osteoporosis drug), it will take more than 2 years before the drug can be prescribed from hospital pharmacies. Although some patients have bought the drug from the United States, Taiwan, and Hong Kong through friends overseas, it is not a convenient route after all. I really hope that the drug will be available in China soon and can be convenient for the majority of patients.